WallStreetZen

NASDAQ: CEMI
Chembio Diagnostics Inc Stock

$2.84+0.05 (1.79%)
Updated Jul 30, 2021
CEMI Price
$2.84
Fair Value Price
N/A
Market Cap
$57.49M
52 Week Low
$2.06
52 Week High
$8.75
P/E
-2.22x
P/B
2.47x
P/S
2.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.33M
Earnings
-$25.02M
Gross Margin
32.9%
Operating Margin
-65.75%
Profit Margin
-72.9%
Debt to Equity
1.47
Operating Cash Flow
-$20M
Beta
0.43
Next Earnings
Aug 4, 2021
Ex-Dividend
N/A
Next Dividend
N/A

CEMI Overview

Zen Score

High
Medium
Low
9
Industry average

Reasons for this score

CEMI is good value based on its book value relative to its share price (2.47x), compared to the US Diagnostics & Research industry average (6.5x)
Valuation
CEMI's cash and short-term investments ($14.35M) cannot cover CEMI's cash burn for the next year ($24.66M), once increasing cash burn (167.95%) is accounted for
Financials
CEMI's profit margin has decreased (-25.3%) in the last year from (-47.6%) to (-72.9%)
Financials

1 of 7

CEMI News

Valuation

CEMI fair value

Fair Value of CEMI stock based on Discounted Cash Flow (DCF)
Price
$2.84
Fair Value
$3.46
Undervalued by
18.01%

CEMI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.22x
Industry
35.33x
Market
31.55x

CEMI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.47x
Industry
6.5x
CEMI is good value based on its book value relative to its share price (2.47x), compared to the US Diagnostics & Research industry average (6.5x)
Valuation

CEMI's financial health

Profit margin

Revenue
$8.7M
Net Income
-$4.5M
Profit Margin
-51.6%
CEMI's cash and short-term investments ($14.35M) cannot cover CEMI's cash burn for the next year ($24.66M), once increasing cash burn (167.95%) is accounted for
Financials
CEMI's profit margin has decreased (-25.3%) in the last year from (-47.6%) to (-72.9%)
Financials

Assets to liabilities

Assets
$57.4M
Liabilities
$34.1M
Debt to equity
1.09
CEMI's short-term assets ($32.27M) exceed its short-term liabilities ($9.43M)
Financials
CEMI's short-term assets ($32.27M) exceed its long-term liabilities ($24.69M)
Financials
CEMI's debt has increased relative to shareholder equity (1.47), over the past 5 years ago (0.16)
Financials
CEMI's debt to equity ratio (1.47) is considered high
Financials

Cash flow

Operating
-$7.3M
Investing
-$1.2M
Financing
-$129.3k
CEMI's cash and short-term investments ($14.35M) cannot cover CEMI's cash burn ($24.66M) for 1 year
Financials

Chembio Diagnostics Stock FAQ

What is Chembio Diagnostics's quote symbol?

(NASDAQ: CEMI) Chembio Diagnostics trades on the NASDAQ under the ticker symbol CEMI. Chembio Diagnostics stock quotes can also be displayed as NASDAQ: CEMI.

What is the 52 week high and low for Chembio Diagnostics (NASDAQ: CEMI)?

(NASDAQ: CEMI) Chembio Diagnostics's 52-week high was $8.75, and its 52-week low was $2.06. It is currently -67.54% from its 52-week high and 37.86% from its 52-week low.

How much is Chembio Diagnostics stock worth today?

(NASDAQ: CEMI) Chembio Diagnostics currently has 20,244,554 outstanding shares. With Chembio Diagnostics stock trading at $2.84 per share, the total value of Chembio Diagnostics stock (market capitalization) is $57.49M.

Chembio Diagnostics stock was originally listed at a price of $9.20 in May 5, 2004. If you had invested in Chembio Diagnostics stock at $9.20, your return over the last 17 years would have been -69.13%, for an annualized return of -6.68%.

How much is Chembio Diagnostics's stock price per share?

(NASDAQ: CEMI) Chembio Diagnostics stock price per share is $2.84 today (as of Jul 30, 2021).

What is Chembio Diagnostics's Market Cap?

(NASDAQ: CEMI) Chembio Diagnostics's market cap is $57.49M, as of Aug 1, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Chembio Diagnostics's market cap is calculated by multiplying CEMI's current stock price of $2.84 by CEMI's total outstanding shares of 20,244,554.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.